SCHEMBL4054636

SCHEMBL4054636

O=S1(=O)N(CCCCNC2CCCCC2)c2ccccc2N1c1c(F)cccc1F

nearest known ligand 0.56

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 17/20 0.56
SLC6A4 P31645 9/20 0.56
SLC6A3 Q01959 7/20 0.51
KCNH2 Q12809 1/20 0.50
DRD2 P14416 1/20 0.38
DRD3 P35462 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4063654 0.97 SLC6A2 (0.55) SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL4061954 0.97 SLC6A2 (0.57) SLC6A2SLC6A4SLC6A3KCNH2DRD2
Hydrochloric Acid SCHEMBL4949397 0.96 SLC6A2 (0.56) SLC6A2SLC6A4SLC6A3KCNH2DRD2
Hydrochloric Acid SCHEMBL4945786 0.96 SLC6A2 (0.54) SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL4055247 0.96 SLC6A2 (0.58) SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL4058027 0.96 SLC6A2 (0.56) SLC6A2SLC6A4SLC6A3KCNH2
Hydrochloric Acid SCHEMBL4942314 0.94 SLC6A2 (0.57) SLC6A2SLC6A4SLC6A3KCNH2
Hydrochloric Acid SCHEMBL4944273 0.94 SLC6A2 (0.55) SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL4054331 0.93 SLC6A2 (0.56) SLC6A2SLC6A4SLC6A3KCNH2
Hydrochloric Acid SCHEMBL4944985 0.92 SLC6A2 (0.55) SLC6A2SLC6A4SLC6A3KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2061776-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE Wyeth a Corporation of the State of Delaware (US) 2009-05-27 EP claimed
US-20080161366-A1 AMINOALKYL SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2008-07-03 US claimed
WO-2008073459-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2008-06-19 WO claimed
EP-2061776-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE Wyeth a Corporation of the State of Delaware (US) 2009-05-27 EP disclosed
US-20080161366-A1 AMINOALKYL SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2008-07-03 US disclosed
US-20080161366-A1 AMINOALKYL SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2008-07-03 US disclosed
US-20080161366-A1 AMINOALKYL SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2008-07-03 US disclosed
WO-2008073459-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2008-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161366-A1 AMINOALKYL SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE SLC6A4, SLC6A2, SLC6A3 SLC6A2 2/4885SLC6A4 1/4885SLC6A3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.